Neuroimaging as progression and outcome markers in clinical trials of movement disorders: Are we ready?
Neuroimaging biomarkers are essential for assessing movement disorders like Parkinson's disease. Various imaging techniques, including MRI, help evaluate disease progression, but reliable biomarkers remain elusive. Differentiating Parkinson's from other disorders is crucial, and studies show a link between neuroimaging findings and clinical measures. The focus is on surrogate endpoints, early intervention, and the need for ongoing research to improve treatment outcomes.Speaker: Nicola Pavese
Level: Advanced
Topics in this course:
